Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
αPD1-MSLN-CAR T cells in MSLN-positive advanced solid tumors
NCT04503980Phase 1Unknown
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M28z1XXPD1DNR in solid tumor, ovarian cancer, cholangiocarcinoma (CCA) and 1 more, sponsored by Shanghai Cell Therapy Group. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
M28z1XXPD1DNR
03
Conditions
solid tumorovarian cancercholangiocarcinoma (CCA)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04503980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503980.